ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Cardiovascular Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,989Medicare Part D Prescriptions Filled, Including Refills

Rank: 53 out of 1448

$723K Total Retail Price of All Prescriptions

Rank: 61 out of 1448

410 Patients Receiving at Least One Drug in Part D
66%Patients 65 Years and Older
58% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in California
Lower avg

Schedule Two
Controlled Substances

23% of this provider’s 410 patients filled at least one prescription for a schedule two drug, compared to an average of 0%.

Schedule Three
Controlled Substances

34% of this provider’s 410 patients filled at least one prescription for a schedule three drug, compared to an average of 2%.

Risky Drugs to Seniors

3% of this provider’s 6,751 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 28%.

Prescription Price

$66 was the average price of a prescription from this provider, compared to $67 among peers.

Prescriptions per Patient

27 is the average number of prescriptions (including refills) per patient, compared to an average of 12.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in California
HYDROCODONE-ACETAMINOPHEN 672 404 S3 1 33
LISINOPRIL 457 294 2 5
CARVEDILOL 338 282 3 1
SIMVASTATIN 302 249 4 3
ZOLPIDEM TARTRATE 241 172 5 34
FUROSEMIDE 204 135 6 7
OMEPRAZOLE 203 138 7 23
ATORVASTATIN CALCIUM 198 153 8 4
LEVOTHYROXINE SODIUM 194 137 9 21
METFORMIN HCL 166 102 10 25
AMLODIPINE BESYLATE 157 115 11 2
WARFARIN SODIUM 155 123 12 8
GABAPENTIN 145 38 13 51
METHADONE HCL 139 11 S2 14 301
PROAIR HFA 114 57 15 104
ATENOLOL 113 76 16 12
SERTRALINE HCL 109 49 17 99
BACLOFEN 109 53 17 166
MELOXICAM 107 68 19 73
CYMBALTA 104 61 20 123
MORPHINE SULFATE ER 104 38 S2 20 275
ALLOPURINOL 103 96 22 43
NAPROXEN 100 79 23 112
ESTRADIOL 100 31 R 23 198
TAMSULOSIN HCL 92 71 25 46
HYDROCHLOROTHIAZIDE 88 65 26 18
AMIODARONE HCL 87 77 27 22
TERAZOSIN HCL 86 63 28 116
CRESTOR 86 53 28 17
TRAZODONE HCL 86 43 28 128
CARISOPRODOL 85 0 R 31 176
NEXIUM 84 45 32 49
ROPINIROLE HCL 81 58 33 158
ENALAPRIL MALEATE 81 77 33 48
FINASTERIDE 81 76 33 141
PANTOPRAZOLE SODIUM 81 42 33 42
DIGOXIN 78 52 37 13
CLOPIDOGREL 78 62 37 10
FENTANYL 77 42 S2 39 284
KLOR-CON 10 77 47 39 102
OXYCODONE HCL-ACETAMINOPHEN 76 11 S2 41 288
AMITRIPTYLINE HCL 75 33 R 42 153
FLUOXETINE HCL 74 27 43 164
CYCLOBENZAPRINE HCL 68 30 R 44 214
TRAMADOL HCL-ACETAMINOPHEN 66 39 45 202
PROMETHAZINE HCL 66 18 R 45 209
DEXILANT 63 0 47 87
SPIRONOLACTONE 63 34 47 24
DOXYCYCLINE HYCLATE 62 41 49 283
IPRATROPIUM BROMIDE 57 26 50 271
HYDROMORPHONE HCL 56 0 S2 51 278
LOSARTAN POTASSIUM 56 39 51 11
MIRTAZAPINE 56 42 51 181
SULFAMETHOXAZOLE-TRIMETHOPRIM 56 34 51 151
ADVAIR DISKUS 55 38 55 74
DILTIAZEM 24HR ER 55 51 55 52
LOVASTATIN 52 34 57 35
PLAVIX 52 39 57 14
LANTUS 52 34 57 111
VENTOLIN HFA 52 27 57 196
ABILIFY 50 36 61 254
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 20, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.